youtube_live
Q3 2026 earnings • released • EPS beat +16.14% • Revenue beat +3.15%
See resultschevron_right
LIVN:NASDAQ
LivaNova PLC
$89.99
arrow_downward
-1.26%(-1.15) 1D
$89.99
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 6, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LIVN...
Open
$90.08
High
$91.51
Low
$88.42
Mkt. cap
4.96B
Avg. vol.
725.38K
Volume
444.00K
P/E ratio
25.77
52-wk high
$99.38
52-wk low
$49.73
EPS
$3.49
Beta
0.91
Shares outstanding
55.09M
No. of employees
3K
Open
$90.08
High
$91.51
Low
$88.42
Mkt. cap
4.96B
Avg. vol.
725.38K
Volume
444.00K
P/E ratio
25.77
52-wk high
$99.38
52-wk low
$49.73
EPS
$3.49
Beta
0.91
Shares outstanding
55.09M
No. of employees
3K
News stories
From web sources and news partners
Yahoo Finance
·
2 days ago
LivaNova PLC (LIVN) (Q3 2026) Earnings Call Highlights: Double-Digit Growth Fuels Raised ...
Kalkine
·
2 days ago
How Did LivaNova (NASDAQ:LIVN) Perform in Q3 2026, and What Does Its Raised Guidance Signal?
Yahoo Finance
·
2 days ago
LivaNova PLC Q3 2026 Earnings Call Summary
Profile
LivaNova, plc is a medical device manufacturer that is a foreign domiciled company based in the U.K. for tax inversion purposes. With operational headquarters in the United States. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN". Wikipedia
About LivaNova PLC
CEOVladimir Makatsaria
Employees3.3K
Founded1987
Headquarters-
SectorHealth Care
IndustryMedical device
Websitelivanova.com
Analyst ratings
Based on 7 analysts giving stock ratings to LIVN in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for LIVN in the last 3 months.
Highest
Current $89.99
$120.00 (+33.35%)
Average
$104.00 (+15.57%)
Lowest
$75.00 (-16.66%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Anthony Petrone Mizuho Securities | Buy | Maintained | $115.00 | +27.8% | 11/05/2026 |
David Rescott Robert W. Baird | Buy | Maintained | $111.00 | +23.3% | 11/05/2026 |
Christopher Pasquale Barclays | Buy | Maintained | $105.00 | +16.7% | 11/05/2026 |
Matthew Taylor Jefferies | Buy | Reiterated | $120.00 | +33.3% | 11/04/2026 |
Michael Matson Needham | Buy | Maintained | $112.00 | +24.5% | 11/04/2026 |
Matt Miksic Barclays | Buy | Maintained | $105.00 | +16.7% | 10/07/2026 |
Adam Maeder Piper Sandler | Buy | Reiterated | $90.00 | +0% | 09/02/2026 |
Keith Hinton Freedom Capital Markets | Hold | Maintained | $75.00 | -16.7% | 08/20/2026 |
Rick Wise Stifel Nicolaus | Buy | Maintained | $85.00 | -5.5% | 08/05/2026 |
Brett Fishbin KeyBanc | Buy | Reiterated | $92.00 | +2.2% | 06/22/2026 |
David Roman Goldman Sachs | Hold | Maintained | $72.00 | -20% | 05/06/2026 |
Last report
Nov 4, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$1.23 / $1.06
+16.14%beat
arrow_upward
Revenue / Est. (USD)
393.10M / 381.11M
+3.15%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 360.92M | 362.26M | 390.59M | 393.10M |
Cost of goods sold | 120.05M | 117.41M | 125.62M | 128.10M |
Cost of revenue | 120.05M | 117.41M | 125.62M | 128.10M |
Research and development expenses | 48.52M | 49.14M | 52.86M | 47.70M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 143.66M | 143.57M | 158.13M | 154.90M |
Operating expense | 194.07M | 192.71M | 212.07M | 236.60M |
Total operating expenses | 314.12M | 310.12M | 337.68M | 364.70M |
Operating income | 46.81M | 52.14M | 52.90M | 28.40M |
Other non operating income | 378.36M | -7.53M | -38.73M | 100.00K |
EBT including unusual items | 27.62M | 26.63M | 18.36M | 46.70M |
EBT excluding unusual items | 393.28M | 38.44M | 8.14M | 46.70M |
Income tax expense | -3.28M | 4.34M | -90.20M | 12.40M |
Effective tax rate | -11.88% | 16.29% | -491.17% | 26.55% |
Other operating expenses | 1.88M | - | 1.08M | 34.00M |
Net income | 30.91M | 22.29M | 108.57M | 34.30M |
Net profit margin | 8.56% | 6.15% | 27.80% | 8.73% |
Earnings per share | 0.86 | 0.98 | 1.26 | 1.23 |
Interest and investment income | 4.46M | 3.55M | 3.83M | - |
Interest expense | -10.86M | -8.29M | -7.18M | -8.00M |
Net interest expenses | -6.40M | -4.74M | -3.34M | -8.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 58.88M | 65.00M | 68.32M | 43.92M |
Gain or loss from assets sale | -4.13M | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events